Search | Clinical Trials Finder

Conditions: Seasonal Allergic Rhinitis
Interventions: Fluticasone propionate, Flonase®, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years and older
Enrollment: 1,474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Seasonal Allergic Rhinitis
Interventions: Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 12 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Seasonal Allergic Rhinitis
Interventions: Nasal CO2, Inactive Placebo Gas; Drug
Lead sponsor: Capnia, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Seasonal Allergic Rhinitis
Interventions: Mometasone Furoate Nasal Spray, 50 mcg, Nasonex Nasal Spray, 50 mcg, Placebo Nasal Spray; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 811 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 10
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo nasal spray, 0.15% azelastine hydrochloride Nasal Spray; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 34
States / cities: Huntington Beach, California • Long Beach, California • San Diego, California + 30 more

Conditions: Seasonal Allergic Rhinitis
Interventions: STAHIST, Placebo; Drug
Lead sponsor: Magna Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 8
States / cities: Stockbridge, Georgia • South Bend, Indiana • Louisville, Kentucky + 5 more

Conditions: Allergy
Interventions: ALK Ragweed Tablet; Biological
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hay Fever, Seasonal Allergic Rhinitis
Interventions: Ciclesonide nasal spray; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 71
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Costa Mesa, California + 65 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo, 0.15% Azelastine Hydrochloride; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 536 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more

Conditions: Rhinitis, Allergic, Seasonal
Interventions: fluticasone furoate, fexofenadine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 42
States / cities: Little Rock, Arkansas • Albany, Georgia • Columbus, Georgia + 37 more

Conditions: Seasonal Allergic Rhinitis, Hay Fever
Interventions: Beclomethasone dipropionate, Placebo Nasal Aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more

Conditions: Allergic Rhinitis
Interventions: Placebo, VAK694, Fluticasone; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Duncansville, Pennsylvania

Conditions: Seasonal Allergic Rhinitis
Interventions: Fexofenadine HCl; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 15 Years and older
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type I Hypersensitivity
Interventions: TreeMATA MPL; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 10
States / cities: Mission Viejo, California • San Jose, California • Woodstock, Georgia + 7 more

Conditions: Hayfever, Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
Interventions: fluticasone furoate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 4
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas

Conditions: Seasonal Allergic Rhinitis (SAR)
Interventions: GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 1,176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 43
States / cities: Mission Viejo, California • Orange, California • San Diego, California + 33 more

Conditions: Seasonal Allergic Rhinitis
Interventions: levocetirizine dihydrochloride, placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 38
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 35 more

Conditions: Seasonal Allergic Rhinitis
Interventions: ACT-129968, Cetirizine, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: FPNS, FFNS, placebo FFNS, placebo FPNS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 20 more

Conditions: Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
Interventions: Intra-lymphatic allergenic extract, Intra-lymphatic placebo; Biological
Lead sponsor: Christopher Thompson, MD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Austin, Texas • Grapevine, Texas • San Antonio, Texas

Conditions: Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis
Interventions: PL-14 Allergy Blocker, Ayr® Saline Nasal Mist; Device
Lead sponsor: Polyrizon Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Normal, Illinois • St Louis, Missouri • Ocean City, New Jersey + 2 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: GW685698X; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 65
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 58 more

Conditions: Seasonal Allergic Rhinitis, SAR
Interventions: BDP HFA, Placebo nasal aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 715 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 45
States / cities: Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 12 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more

Search by objective public record fields.

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Trial of STAHIST in Seasonal Allergic Rhinitis

Safety of ALK Ragweed Tablet

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

Study In Adults And Adolescents With Seasonal Allergic Rhinitis

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis In Pediatric Subjects

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis